Clinical Trial Aims to Break Urinary Tract Infections

For millions of women, the dreaded, familiar twinge of a urinary tract infection (UTI) is an all-too-common reality. Ranking as the second most prevalent infection nationwide, UTIs can be disruptive, painful, and frustratingly recurrent. While antibiotics are the standard treatment, a growing movement is focused on a more proactive approach: prevention. Leading this charge is Uqora, a company developing innovative products to combat UTIs, and they’re putting their science to the test.

Uqora has launched a significant clinical trial to scientifically validate the effectiveness of a new daily supplement designed to give women control over their urinary health. This step underscores a commitment to evidence-based solutions in a space that has long needed them.

Inside the Study: A Search for Proof

The clinical trial, officially titled “Uqora Supplements in Women With UTIs,” is a meticulously designed virtual study that began in August 2019. Its core purpose is straightforward: to determine if Uqora’s daily dietary supplement can effectively reduce the frequency of urinary tract infections.

To ensure unbiased results, the research is conducted as a blind trial. The 360 participants are divided into two groups:

• The Experimental Group: Receives a 180-day supply of Uqora’s drink mix and capsules.
• The Control Group: Receives a placebo drink mix and capsules that look identical to the real product.

For six months, each woman in the study incorporates the supplements into her daily routine, tracks any occurrence of a UTI, and maintains a weekly online diary to log her experiences through a simple questionnaire. The working hypothesis is that the group taking the Uqora products will experience a significantly greater decrease in UTIs compared to the placebo group. To standardize factors that could influence results, all participants are advised to maintain hydration, including the consumption of cranberry juice or extract, and monitor their own hydration levels.

Who is a Part of This Landmark Research?

The study’s criteria were carefully selected to focus on those most affected by this issue. The research includes 360 women aged 18 and older who have a history of recurrent UTIs, defined as experiencing at least two infections in the last six months.

To maintain the integrity of the data, participants were required to be in good general health and able to swallow pills. The study excluded individuals with underlying conditions that could complicate the results, such as diabetes, chronic kidney stones, or multiple sclerosis, as well as those who use a catheter, are pregnant, or were already using Uqora products.

The Personal Mission Fueling the Science

Behind every innovative company is a powerful “why,” and Uqora’s is deeply personal. The company was founded by Jenna Ryan, who suffered from a relentless cycle of UTIs herself—enduring as many as eight a year. After being told there was little she could do to prevent them, she refused to accept the status quo. Ryan founded Uqora to research and create high-quality, effective UTI prevention methods, turning her personal struggle into a mission to help others.

Today, Uqora has already helped over 50,000 women with a range of products tailored to different needs, from flushing out bacteria to providing extra protection for those who are sexually active. This clinical trial is the next logical step in their journey. By investing in rigorous scientific research, Uqora is not just validating its own products but is also helping to raise the bar for the entire industry.

Uqora’s clinical trial represents more than just a test for a new supplement; it signifies a crucial shift in the conversation around urinary health—moving from reactive treatment to proactive empowerment. As we await the results, one thing is clear: dedicated, science-backed research is paving the way for a future where women are no longer at the mercy of recurrent UTIs.